FDA’s Cardio-Renal Division Kicks Off August With Three Approvals
This article was originally published in The Pink Sheet Daily
Executive Summary
The Medicines Co.’s IV therapy Cleviprex plus Novartis’ drug-drug combos, Exforge and Diovan HCT, are approved.
You may also be interested in...
The Medicines Company’s Curacyte Acquisition Points To A Post-Angiomax Future
Deal expands TMC’s pipeline, with an eye on the antifibrinolytic market left empty by the Trasylol withdrawal.
The Medicines Company’s Curacyte Acquisition Points To A Post-Angiomax Future
Deal expands TMC’s pipeline, with an eye on the antifibrinolytic market left empty by the Trasylol withdrawal.
Wooing Partners, Pharmacopeia Shifts DARA To Kidney Disease
Cash-light firm’s move away from the crowded hypertension space could clinch a deal.